SOAT1 and acute myeloid leukemia: These mutations collectively account for up to 50% of all acute myeloid leukemia (AML) cases and present leukemic cell proliferation and survival benefits by activating the genes that signal the RAS-MAP kinase, PI3K, and STAT pathways.